How is progressive supranuclear palsy treated
Levodopa and dopamine agonists are the most frequently used agents in the treatment of progressive supranuclear palsy.
However, even with high doses, they usually provide only a transient and slight improvement of parkinsonian symptoms.
The loss of dopamine receptors in the striatum and the presence of extensive lesions involving other neurotransmitters, such as acetylcholine, probably account for the failure of pharmacologic therapy.
Currently, no drug provides sustained relief in patients with progressive supranuclear palsy.
With progression of disease, patients usually become bedridden, unable to swallow and talk.
Gastrostomy is necessary in advanced stages.
Death, usually related to respiratory complications, occurs after a mean disease duration of 7 to 8 years.